Navigation Links
Cytos Invites to the Annual Shareholders' Meeting 2013
Date:6/5/2013

ZURICH, June 6, 2013 /PRNewswire/ --

Cytos Biotechnology Ltd ("Cytos") today announced that the Annual Shareholders' Meeting 2013 will take place on Friday, 28 June 2013, at 10 a.m. at Cytos' offices in Schlieren/Zurich (Switzerland). The invitation including the agenda is available for downloading at

http://www.cytos.com/uploads/2013/Cytos_GV_Invitation_FINAL_2013.pdf

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company's lead product candidate CYT003 is a first-in-class immune modulator in Phase 2 clinical development as a potential new treatment for allergic asthma.

CYT003 acts via a novel, allergen-independent mechanism of action to selectively suppress the body's immune response to allergens, a predominant risk factor for asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function in patients with persistent allergic asthma, even as standard inhaled corticosteroid treatment was withdrawn. CYT003 has been shown to be safe in over 450 patients to date.

Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

http://www.cytos.com 

This foregoing press release may contain forward-looking statements that include words or phrases such as "are intended for", "are designed to", or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The Company assumes no responsibility to update forward-looking statements or adapt them to future events or developments.


'/>"/>
SOURCE Cytos Biotechnology Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. A*STAR and Cytos Bring Singapores First Influenza Vaccine to Clinical Testing
2. Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-IgE Vaccine
3. CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers
4. Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
5. DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call
6. Cardinal Health Foundation Invites Local Non-profit Organizations To Apply For Grants To Prevent Prescription Drug Abuse
7. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2013 Financial Results Conference Call
8. DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call
9. DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
10. Heraeus Survey Invites Customers to Share "What they Really Think"
11. Total Therapeutic Management, Inc. invites directors of quality improvement to learn secrets of provider engagement strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... May 24, 2016 ... , la première endoprothèse à double ... à l,intervention portant sur les membres inférieurs ... OrbusNeich, entreprise mondiale spécialisée dans la ... la vie, a élargi son portefeuille pour ...
(Date:5/23/2016)... , May 23, 2016 ... Handling Equipment Market by Product (Wheelchair, Scooters, Medical ... (Bariatric Care, Critical Care, Wound), Accessories (Lifting, Transfer) ... to 2021", published by MarketsandMarkets, the patient handling ... Billion by 2021 at a CAGR of 10.5% ...
(Date:5/23/2016)... 23, 2016 According to ... Development, Growth and Demand Forecast to 2022 - ... by Application (Drug Discovery and Development, Proteomics, Clinical ... Life Science and Biotechnology, Academic and Research Institute, ... the global mass spectrometry market was ...
Breaking Medicine Technology:
(Date:5/24/2016)... NY (PRWEB) , ... May 24, 2016 , ... Growing ... this growing trend, more gluten-free products are available and easily accessible. Whether someone chooses ... want to cater to a certain diet, King Kullen Grocery stocks their shelves with ...
(Date:5/24/2016)... ... May 24, 2016 , ... The number of health ... or 10% over last year, according to data in the forthcoming AIS’s Directory ... comparatively stable, with a slight decrease in risk-based groups and a slight increase ...
(Date:5/24/2016)... CA (PRWEB) , ... May 24, 2016 , ... As ... performed the first penis transplant in the United States . The 64-year-old patient ... with penile cancer. The transplant could restore not only a natural appearance, but also ...
(Date:5/24/2016)... ... ... In light of recent heavy flooding in Houston, Texas, Pelican Water Systems is ... Houston area. , Heavy floodwaters have led to destroyed waterways and flooded reservoirs. The ... even be aware of the contamination of their water supply and thus, may be ...
(Date:5/24/2016)... ... May 24, 2016 , ... Aloria Health Announces ... Begin In June , Aloria Health, specializing in a re-imagined, client-oriented approach to ... Milwaukee, its first treatment facility for outpatient, day treatment and residential care. Aloria ...
Breaking Medicine News(10 mins):